Systemic Inflammation

6

Review clinical trials related to Systemic Inflammation. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions

Background: Inflammatory conditions can cause symptoms like fevers, arthritis, and rash. Systemic juvenile idiopathic arthritis (sJIA) is one of these conditions. So is adult-onset Still s disease (AOSD). Their causes are unknown. Researchers want to learn more about these conditions. This includes genetic changes and environmental factors. Objective: To study sJIA and AOSD in children and adults over time. Eligibility: People with known or suspected sJIA, AOSD, or similar inflammatory condition Design: Participants will be screened with a phone call. Participants will have 1 visit. It may be outpatient or they may be admitted to the clinic. The visit may last up to 5 days. Participants will have: * Medical history * Physical exam * Musculoskeletal exam * Questions about overall health and quality of life, disease activity, functional status, and cognitive ability. Participants may also have: * Pictures taken of their skin, joints, or spine * Blood, urine, and stool tests * Scans or X-rays of joints with arthritis * Chest X-ray * Heart tests * Skin biopsy. The skin will be numbed. The top layers of a small area will be scraped off. Participants who have a joint aspiration may provide a fluid sample. The joint will be prepared, then fluid is removed by needle. A corticosteroid may be injected. Participants who have a bone marrow biopsy may provide sample cells. Participants may be seen by NIH specialists. Members of the participant s family and healthy volunteers may give blood or saliva samples for genetic testing. Participants may repeat some study tests every 6 months.

Participants needed: 2,000
Trial details
Age: 1-100Biological sex: AllType: ObservationalSponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Updated: Jul 2, 2026Locations: 1
Eligibility criteria

Patients less than 16 years of age will be considered to have sJIA if they meet... [+11]

Status: Recruiting

Effects of Dietary Supplementation With omega3-fatty Acids (Fish Oil) and Progressive Resistance Training on Skeletal Muscle Status in Gynaecological, Gastrointestinal and Urological Cancer Patients

Cancer cachexia is a common and prognostically relevant complication of advanced malignancies, characterized by systemic inflammation, increased catabolism, and reduced nutritional intake, leading to a progressive loss of skeletal muscle mass, physical performance, and quality of life. Muscle wasting negatively affects the tolerability and efficacy of oncological therapies and exacerbates distressing symptoms such as fatigue. Consequently, international guidelines recommend combined nutritional and exercise interventions as key components of supportive cancer care. However, due to treatment-related limitations, conventional exercise programs are often difficult to implement, highlighting the need for feasible, time-efficient, and individually adaptable training concepts suitable for daily life. In addition, adequate protein-rich nutrition is essential and may be supported by targeted nutritional supplementation. Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have demonstrated anti-inflammatory effects and beneficial influences on nutritional status, quality of life, and potentially skeletal muscle mass. The aim of the present project is to investigate, in a randomized, placebo-controlled trial, whether the combination of progressive resistance training (twice-weekly TheraBand-based exercise) and omega-3 supplementation (daily intake of 2 g EPA and 1 g DHA administered as fish oil capsules) can improve muscle status, physical performance, and patient-relevant outcomes such as quality of life, appetite, and fatigue in cancer patients at high risk of developing cancer cachexia.

Participants needed: 288
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of Erlangen-Nürnberg Medical SchoolUpdated: Jun 11, 2026Locations: 1
Eligibility criteria

Patients with malignant tumors undergoing curative or palliative treatment, incl... [+2]

Patients younger than 18 years [+6]

Status: Recruiting

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.

Participants needed: 100
Trial details
Phase: Phase 4Age: 18-64Biological sex: AllType: InterventionalSponsor: University of Alabama at BirminghamUpdated: Apr 22, 2026Locations: 1
Eligibility criteria

Provision of signed and dated informed consent. [+15]

Inability to give informed consent. [+29]

Status: Recruiting

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.

Participants needed: 680
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Novo Nordisk A/SUpdated: Apr 7, 2026Locations: 240
Eligibility criteria

Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2 mi... [+14]

Myocardial infarction, stroke, unstable angina pectoris, transient ischaemic att... [+9]

Status: Not yet recruiting

Assessing the Feasibility of Multi-modal Biosensing for Monitoring Mobility and Cognition in Older Adults

Current health devices often overlook older users, who may face both health challenges and technology barriers. We are investigating the feasibility of wearable sensors to track posture, heart rate, and breathing, alongside a microneedle patch that collect body fluids to measure stress and inflammation markers. By combining this data, we aim to create an easy to use system that supports personalized, at home health monitoring for older adults.

Participants needed: 20
Trial details
Age: 65+Biological sex: AllType: ObservationalSponsor: Tufts UniversityUpdated: Oct 20, 2025Locations: 1
Eligibility criteria

Aged 65 or older [+3]

Reliance on assistive walking devices [+5]

Status: Recruiting

Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea

The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.

Participants needed: 24
Trial details
Age: 30-70Biological sex: AllType: InterventionalSponsor: Integrative Skin Science and ResearchUpdated: Aug 27, 2024Locations: 1
Eligibility criteria

Males and females 30 to 70 years of age [+2]

The presence of severe rosacea as noted by the investigator global assessment. [+11]